Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gibble

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
Advances in Therapy|July 11, 2025
Broad Impact of Bowel Urgency in Ulcerative Colitis and Crohn's Disease: US, European, and Japanese Patient and Healthcare Professional Perspectives from the Communicating Needs and Features of IBD Experiences (CONFIDE) SurveyDavid T Rubin, Alison Potts Bleakman, Simon Travis, et al.
Journal of Patient-Reported Outcomes|July 1, 2025
Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumabDavid B Clemow, Marla C Dubinsky, Simin K Baygani, et al.
Crohn'S & Colitis 360|March 30, 2026
Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY studyVipul Jairath, Theresa Hunter Gibble, Laurent Peyrin-Biroulet, et al.
Current Medical Research and Opinion|July 10, 2025
Impact of moderate-to-severe ulcerative colitis and Crohn's disease on sexual activity: United States and European patient perspectives from the communicating needs and features of IBD experiences (CONFIDE) surveyMarla C Dubinsky, Alison Potts Bleakman, Stefan Schreiber, et al.
The Journal of Infectious Diseases|December 12, 1997
Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study GroupE L Murphy, S A Glynn, J Fridey, et al.
Inflammatory Bowel Diseases|January 25, 2024
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT TrialsGeert D'Haens, Peter D R Higgins, Laurent Peyrin-Biroulet, et al.
Transfusion|July 18, 2008
The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006Anne F Eder, Beth A Dy, Jean M Kennedy, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Inflammatory Bowel Diseases|March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Applications in Plant Sciences|April 27, 2026
Assessing the viability of genebanked seeds from rare, wild plants native to the United States using the D.E.A.D. paradigmChristina Walters, Lisa M Hill, Katherine D Heineman, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Advances in Therapy|July 11, 2025
Broad Impact of Bowel Urgency in Ulcerative Colitis and Crohn's Disease: US, European, and Japanese Patient and Healthcare Professional Perspectives from the Communicating Needs and Features of IBD Experiences (CONFIDE) SurveyDavid T Rubin, Alison Potts Bleakman, Simon Travis, et al.
Journal of Patient-Reported Outcomes|July 1, 2025
Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumabDavid B Clemow, Marla C Dubinsky, Simin K Baygani, et al.
Crohn'S & Colitis 360|March 30, 2026
Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY studyVipul Jairath, Theresa Hunter Gibble, Laurent Peyrin-Biroulet, et al.
Current Medical Research and Opinion|July 10, 2025
Impact of moderate-to-severe ulcerative colitis and Crohn's disease on sexual activity: United States and European patient perspectives from the communicating needs and features of IBD experiences (CONFIDE) surveyMarla C Dubinsky, Alison Potts Bleakman, Stefan Schreiber, et al.
The Journal of Infectious Diseases|December 12, 1997
Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study GroupE L Murphy, S A Glynn, J Fridey, et al.
Inflammatory Bowel Diseases|January 25, 2024
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT TrialsGeert D'Haens, Peter D R Higgins, Laurent Peyrin-Biroulet, et al.
Transfusion|July 18, 2008
The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006Anne F Eder, Beth A Dy, Jean M Kennedy, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Inflammatory Bowel Diseases|March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Applications in Plant Sciences|April 27, 2026
Assessing the viability of genebanked seeds from rare, wild plants native to the United States using the D.E.A.D. paradigmChristina Walters, Lisa M Hill, Katherine D Heineman, et al.
Pageof 13